Aripiprazole compositions and methods for its transdermal delivery

Abstract

The present invention discloses compositions of liquid and gel formulation containing aripiprazole in the form of a patch for transdermal delivery.

What is claimed is: 
     
         1 . A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising:
 aripiprazole in the amount of about 1 to 20% w/v;   a gelling agent in the range of about 0.1% to 5% w/v;   an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof;   wherein the pH of the composition is maintained at approximately 6 to 7.   
     
     
         2 . The pharmaceutical composition of  claim 1  wherein the gelling agent is poloxamer. 
     
     
         3 . The pharmaceutical composition of  claim 1  wherein the form is a patch for transdermal delivery. 
     
     
         4 . The pharmaceutical composition of  claim 1  wherein the dosage form is an ointment, cream, emulsion, or liposome. 
     
     
         5 . The pharmaceutical composition of  claim 1  further comprising about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol, and about 5% water. 
     
     
         6 . The pharmaceutical composition of  claim 5 , further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof. 
     
     
         7 . A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising:
 aripiprazole present in the amount of 1 to 20% w/v;   an agent selected from the group consisting of an alcohol, glycol, mineral oil, vegetable oil, and combinations thereof,   an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof;   wherein the pH of the composition is maintained at approximately 6 to 7.   
     
     
         8 . The pharmaceutical composition of  claim 7  wherein the form is a patch for transdermal delivery. 
     
     
         9 . The pharmaceutical composition of  claim 7  being in the dosage form of an ointment, cream, emulsion, or liposome. 
     
     
         10 . The pharmaceutical composition of  claim 7  further comprising about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol, and about 5% water. 
     
     
         11 . The pharmaceutical composition of  claim 10 , further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof. 
     
     
         12 . A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising:
 aripiprazole in the amount of about 1 to 20% w/v;   a gelling agent in the range of about 0.1% to 5% w/v;   an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof;   about 40% N-methyl-2-pyrrolidone, 40% dimethylsulfoxide, 15% alcohol and 5% water;   wherein the pH of the composition is maintained at approximately 6 to 7.   
     
     
         13 . The pharmaceutical composition of  claim 12 , further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof. 
     
     
         14 . A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising:
 aripiprazole present in the amount of 1 to 20% w/v;   an agent selected from the group consisting of an alcohol, glycol, mineral oil, vegetable oil, and combinations thereof,   an enhancer selected from the group consisting of dimethylacetamide, dimethylformamide, decymethylsulfoxide, terpene and terpenoids, liposomes, niosomes, transferomes, ethanosomes, urea, lauric acid, myristc acid, and combinations thereof;   about 40% N-methyl-2-pyrrolidone, about 40% dimethylsulfoxide, about 15% alcohol and about 5% water;   wherein the pH of the composition is maintained at approximately 6 to 7.   
     
     
         15 . The pharmaceutical composition of  claim 14 , further comprising ingredients selected form the group consisting of isopropyl alcohol, isopropyl myristate, PEG, and combinations thereof. 
     
     
         16 . A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in gel form, comprising about 2% ARPZ; about 25% DMSO; about 10% NMP; about 5% isopropyl alcohol (IPA); about 40% Ethyl Alcohol; about 15% PEG 400; about 0.5% carbomer; water q.s. to 100%. 
     
     
         17 . The pharmaceutical composition of  claim 16 , wherein the pH of the composition is maintained at approximately 6 to 7. 
     
     
         18 . A pharmaceutical composition comprising aripiprazole in a dosage form for transdermal delivery, wherein the aripiprazole is in liquid form, comprising about 2% ARPZ; about 25% DMSO; about 10% NMP; about 5% isopropyl alcohol (IPA); about 40% Ethyl Alcohol; about 15% PEG 400; about 0.5% carbomer; water q.s. to 100%. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the pH of the composition is maintained at approximately 6 to 7.